UA96449C2 - Stable laquinimod preparations - Google Patents

Stable laquinimod preparations

Info

Publication number: UA96449C2
Authority: UA; Ukraine
Prior art keywords: preparations; stable; stable laquinimod; laquinimod preparations; pharmaceutically acceptable
Prior art date: 2006-06-12

Application number

UAA200900145A

Other languages

English (en)

Inventor

Шуламит Паташник

Даниэлла Лихт

Адриан Гилберт

Original Assignee

Тева Фармасьютикл Индастриз, Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-12

Filing date

2007-06-12

Publication date

2011-11-10

2007-06-12 Application filed by Тева Фармасьютикл Индастриз, Лтд. filed Critical Тева Фармасьютикл Индастриз, Лтд.

2011-11-10 Publication of UA96449C2 publication Critical patent/UA96449C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Composite Materials (AREA)
Mechanical Engineering (AREA)

UAA200900145A 2006-06-12 2007-06-12 Stable laquinimod preparations UA96449C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81324706P	2006-06-12	2006-06-12

Publications (1)

Publication Number	Publication Date
UA96449C2 true UA96449C2 (en)	2011-11-10

Family

ID=38832466

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200900145A UA96449C2 (en)	2006-06-12	2007-06-12	Stable laquinimod preparations

Country Status (27)

Country	Link
US (3)	US7989473B2 (ru)
EP (1)	EP2035001B1 (ru)
JP (1)	JP5226678B2 (ru)
KR (4)	KR101495327B1 (ru)
CN (1)	CN101466379B (ru)
AR (1)	AR061348A1 (ru)
AT (1)	ATE532515T1 (ru)
AU (1)	AU2007258366B2 (ru)
BR (1)	BRPI0713694A2 (ru)
CA (2)	CA2899472C (ru)
CY (1)	CY1113003T1 (ru)
DK (1)	DK2035001T3 (ru)
EA (1)	EA018031B1 (ru)
ES (1)	ES2377149T3 (ru)
HR (1)	HRP20120093T1 (ru)
IL (1)	IL195724A (ru)
MX (1)	MX2008015808A (ru)
NO (1)	NO342485B1 (ru)
NZ (1)	NZ573846A (ru)
PL (1)	PL2035001T3 (ru)
PT (1)	PT2035001E (ru)
RS (1)	RS52169B (ru)
SI (1)	SI2035001T1 (ru)
TW (1)	TWI400073B (ru)
UA (1)	UA96449C2 (ru)
WO (1)	WO2007146248A2 (ru)
ZA (1)	ZA200810790B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
KR101440982B1 (ko) *	2005-10-19	2014-09-17	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드 나트륨의 결정 및 이의 제조방법
US7989473B2 (en)	2006-06-12	2011-08-02	Teva Pharmaceutical Industries, Ltd.	Stable laquinimod preparations
US8178127B2 (en) *	2007-12-20	2012-05-15	Teva Pharmaceuticals Industries, Ltd.	Stable laquinimod preparations
JP2012502038A (ja) *	2008-09-03	2012-01-26	テバファーマシューティカルインダストリーズリミティド	免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
DE102010048788A1 (de)	2009-02-13	2011-05-19	Amw Gmbh	Transdermales System mit Immunmodulator
DE102009008851A1 (de)	2009-02-13	2010-08-19	Amw Gmbh	Transdermales System mit Immunmodulator
DK2442651T3 (en) *	2009-06-19	2015-09-21	Teva Pharma	Treatment of multiple sclerosis with laquinimod
MX2012001333A (es) *	2009-07-30	2012-06-01	Teva Pharma	Tratamiento de la enfermedad de crohn con la laquinimod.
PT2467372T (pt)	2009-08-10	2016-08-23	Teva Pharma	Tratamento de distúrbios relacionados com bdnf usando laquinimod
DE102010026879A1 (de)	2010-02-11	2011-08-11	AMW GmbH, 83627	Transdermales System mit Immunmodulator
KR20160129093A (ko) *	2010-03-03	2016-11-08	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드를 이용한 루푸스 신장염의 치료
SG183513A1 (en) *	2010-03-03	2012-09-27	Teva Pharma	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
AU2011223702B2 (en) *	2010-03-03	2016-07-14	Teva Pharmaceutical Industries Ltd.	Treatment of lupus arthritis using laquinimod
EP2590653A4 (en) *	2010-07-09	2014-01-01	Teva Pharma	5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
CN104610144A (zh)	2010-07-09	2015-05-13	泰华制药工业有限公司	氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
SG10201509831XA (en) *	2010-12-07	2015-12-30	Teva Pharma	Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
IN2014MN00333A (ru) *	2011-07-28	2015-09-25	Teva Pharma
JP2014521659A (ja) *	2011-07-28	2014-08-28	テバファーマシューティカルインダストリーズリミティド	ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
EP2766020A4 (en) *	2011-10-12	2015-04-01	Teva Pharma	TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
JP2015505564A (ja)	2012-02-03	2015-02-23	テバファーマシューティカルインダストリーズリミティド	第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja)	2012-02-16	2017-10-18	テバファーマシューティカルインダストリーズリミティド	Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
US20130259856A1 (en) *	2012-03-27	2013-10-03	Teva Pharmaceutical Industries, Ltd.	Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) *	2012-05-08	2013-12-16	Teva Pharma	Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) *	2012-06-26	2013-12-26	The Regents Of The University Of California	Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) *	2012-07-11	2015-02-25	Teva Pharma	Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) *	2012-08-13	2014-03-16	Teva Pharma	用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) *	2012-08-13	2014-03-16	Teva Pharma	用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh)	2012-11-07	2016-08-19	Teva Pharmaceutical Industries Ltd.	拉喹莫德胺盐
MX2015010296A (es) *	2013-02-15	2016-05-05	Teva Pharma	Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2014152009A1 (en)	2013-03-14	2014-09-25	Teva Pharmaceutical Industries Ltd.	Transdermal formulations of laquinimod
US9233927B2 (en) *	2013-03-14	2016-01-12	Teva Pharmaceutical Industries, Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
CN105848653A (zh) *	2013-09-27	2016-08-10	梯瓦制药工业有限公司	用于治疗多发性硬化症的拉喹莫德联合治疗
EP3082814A4 (en) *	2013-12-20	2017-06-21	Teva Pharmaceutical Industries Ltd.	Use of laquinimod to delay huntington's disease progression
EP3094330A4 (en) *	2014-01-17	2017-09-27	Teva Pharmaceutical Industries Ltd	Treatment of crohn's disease using low doses of laquinimod
AU2015253330A1 (en)	2014-04-29	2016-12-01	Teva Pharmaceutical Industries Ltd.	Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CN110193014B (zh) *	2019-06-06	2021-05-11	温州医科大学	一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3024257A (en) *	1961-04-10	1962-03-06	Frosst & Co Charles E	Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr)	1976-02-11	1977-09-09	Roussel Uclaf	Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en)	1981-03-03	1988-01-20	Leo Ab	Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de)	1984-10-10	1986-04-17	Mack Chem Pharm	Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv)	1989-06-09	1989-06-09	Pharmacia Ab	Derivatives of quinoline-3-carboxanilide
HUT60458A (en)	1991-02-01	1992-09-28	Sandoz Ag	Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en)	1994-06-22	1996-07-30	Touitou; Elka	Compositions for applying active substances to or through the skin
CH687615A5 (de) *	1994-09-07	1997-01-15	R W Johnson Pharmaceutical Res	Tropen-Verpackung.
US5912349A (en)	1997-01-31	1999-06-15	Pharmacia & Upjohn Company	Process for the preparation of roquinimex
US20030124187A1 (en)	1997-02-14	2003-07-03	Smithkline Beecham Laboratoires Pharmaceutiques,	Pharmaceutical formulations comprising amoxycillin and clavulanate
SE9801474D0 (sv)	1998-04-27	1998-04-27	Active Biotech Ab	Quinoline Derivatives
US6077851A (en) *	1998-04-27	2000-06-20	Active Biotech Ab	Quinoline derivatives
US6133285A (en)	1998-07-15	2000-10-17	Active Biotech Ab	Quinoline derivatives
US6121287A (en)	1998-07-15	2000-09-19	Active Biotech Ab	Quinoline derivatives
SE9802549D0 (sv)	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
SE9802550D0 (sv)	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
SI1187601T1 (sl)	1999-06-07	2005-12-31	Altana Pharma Ag	Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke
CN100390148C (zh)	1999-10-25	2008-05-28	活跃生物技术有限公司	用于治疗恶性肿瘤的药物
SE0002320D0 (sv)	1999-10-25	2000-06-21	Active Biotech Ab	Malignant tumors
JP2002031610A (ja)	2000-07-14	2002-01-31	Ajinomoto Co Inc	生体分子複合体の界面残基を同定する方法
US6307050B1 (en)	2000-08-29	2001-10-23	R. T. Alamo Venture I Llc	Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en)	2000-12-12	2004-10-12	Multi-Comp, Inc.	Sealed blister assembly
US6706733B2 (en)	2001-05-08	2004-03-16	Dainippon Ink And Chemicals, Inc.	Quinolinone derivative formulation and its production method
US20030119826A1 (en) *	2001-09-24	2003-06-26	Pharmacia Corporation	Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en)	2002-06-12	2005-04-05	Active Biotech Ab	Process for the manufacture of quinoline derivatives
US7560557B2 (en)	2002-06-12	2009-07-14	Active Biotech Ag	Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) *	2002-06-12	2002-06-12	Active Biotech Ab	Process for the manufacture of quinoline derivatives
US8980870B2 (en) *	2002-09-24	2015-03-17	Boehringer Ingelheim International Gmbh	Solid telmisartan pharmaceutical formulations
US7820145B2 (en)	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) *	2003-06-09	2010-09-07	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
AU2003300692A1 (en) *	2003-10-30	2005-05-19	Lupin Ltd.	Stable formulations of ace inhibitors and methods for preparation thereof
SE0400235D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
KR101440982B1 (ko)	2005-10-19	2014-09-17	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드 나트륨의 결정 및 이의 제조방법
US7989473B2 (en)	2006-06-12	2011-08-02	Teva Pharmaceutical Industries, Ltd.	Stable laquinimod preparations
US20080087929A1 (en) *	2006-10-11	2008-04-17	Infineon Technologies Ag	Static random access memory with thin oxide capacitor
US8178127B2 (en)	2007-12-20	2012-05-15	Teva Pharmaceuticals Industries, Ltd.	Stable laquinimod preparations
JP2012502038A (ja)	2008-09-03	2012-01-26	テバファーマシューティカルインダストリーズリミティド	免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
DK2442651T3 (en)	2009-06-19	2015-09-21	Teva Pharma	Treatment of multiple sclerosis with laquinimod
MX2012001333A (es)	2009-07-30	2012-06-01	Teva Pharma	Tratamiento de la enfermedad de crohn con la laquinimod.
PT2467372T (pt)	2009-08-10	2016-08-23	Teva Pharma	Tratamento de distúrbios relacionados com bdnf usando laquinimod
KR20160129093A (ko)	2010-03-03	2016-11-08	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드를 이용한 루푸스 신장염의 치료
SG183513A1 (en)	2010-03-03	2012-09-27	Teva Pharma	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
AU2011223702B2 (en)	2010-03-03	2016-07-14	Teva Pharmaceutical Industries Ltd.	Treatment of lupus arthritis using laquinimod
EP2590653A4 (en)	2010-07-09	2014-01-01	Teva Pharma	5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
CN104610144A (zh)	2010-07-09	2015-05-13	泰华制药工业有限公司	氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途

2007
- 2007-06-12 US US11/811,810 patent/US7989473B2/en active Active
- 2007-06-12 CA CA2899472A patent/CA2899472C/en active Active
- 2007-06-12 PL PL07809468T patent/PL2035001T3/pl unknown
- 2007-06-12 TW TW096121085A patent/TWI400073B/zh not_active IP Right Cessation
- 2007-06-12 NZ NZ573846A patent/NZ573846A/en unknown
- 2007-06-12 MX MX2008015808A patent/MX2008015808A/es active IP Right Grant
- 2007-06-12 AT AT07809468T patent/ATE532515T1/de active
- 2007-06-12 PT PT07809468T patent/PT2035001E/pt unknown
- 2007-06-12 RS RS20120039A patent/RS52169B/sr unknown
- 2007-06-12 HR HR20120093T patent/HRP20120093T1/hr unknown
- 2007-06-12 DK DK07809468.7T patent/DK2035001T3/da active
- 2007-06-12 KR KR1020097000323A patent/KR101495327B1/ko not_active Expired - Fee Related
- 2007-06-12 ZA ZA200810790A patent/ZA200810790B/xx unknown
- 2007-06-12 JP JP2009515443A patent/JP5226678B2/ja not_active Expired - Fee Related
- 2007-06-12 KR KR1020147018170A patent/KR20140091778A/ko not_active Ceased
- 2007-06-12 BR BRPI0713694-3A patent/BRPI0713694A2/pt not_active Application Discontinuation
- 2007-06-12 AR ARP070102573A patent/AR061348A1/es unknown
- 2007-06-12 UA UAA200900145A patent/UA96449C2/ru unknown
- 2007-06-12 KR KR1020157014257A patent/KR20150065951A/ko not_active Ceased
- 2007-06-12 EP EP07809468A patent/EP2035001B1/en active Active
- 2007-06-12 CA CA2654982A patent/CA2654982C/en active Active
- 2007-06-12 CN CN2007800216771A patent/CN101466379B/zh not_active Expired - Fee Related
- 2007-06-12 KR KR1020167001876A patent/KR20160013273A/ko not_active Ceased
- 2007-06-12 WO PCT/US2007/013721 patent/WO2007146248A2/en not_active Ceased
- 2007-06-12 AU AU2007258366A patent/AU2007258366B2/en active Active
- 2007-06-12 ES ES07809468T patent/ES2377149T3/es active Active
- 2007-06-12 EA EA200870599A patent/EA018031B1/ru not_active IP Right Cessation
- 2007-06-12 SI SI200730834T patent/SI2035001T1/sl unknown
2008
- 2008-12-04 IL IL195724A patent/IL195724A/en active IP Right Grant
2009
- 2009-01-12 NO NO20090175A patent/NO342485B1/no not_active IP Right Cessation
2011
- 2011-06-22 US US13/166,210 patent/US20110251235A1/en not_active Abandoned
2012
- 2012-02-07 CY CY20121100127T patent/CY1113003T1/el unknown
- 2012-08-07 US US13/568,940 patent/US8383645B2/en active Active

Also Published As

Publication number	Publication date
KR101495327B1 (ko)	2015-02-24
AU2007258366A1 (en)	2007-12-21
EA018031B1 (ru)	2013-05-30
CA2899472C (en)	2019-04-30
KR20140091778A (ko)	2014-07-22
HRP20120093T1 (hr)	2012-03-31
IL195724A0 (en)	2009-09-01
TW200815006A (en)	2008-04-01
NO342485B1 (no)	2018-05-28
KR20150065951A (ko)	2015-06-15
EP2035001A4 (en)	2009-09-23
SI2035001T1 (sl)	2012-03-30
US7989473B2 (en)	2011-08-02
TWI400073B (zh)	2013-07-01
CN101466379B (zh)	2012-10-31
CY1113003T1 (el)	2016-04-13
CA2654982A1 (en)	2007-12-21
CN101466379A (zh)	2009-06-24
IL195724A (en)	2015-09-24
AR061348A1 (es)	2008-08-20
ATE532515T1 (de)	2011-11-15
WO2007146248A2 (en)	2007-12-21
WO2007146248A3 (en)	2008-12-24
RS52169B (sr)	2012-08-31
US20070293537A1 (en)	2007-12-20
NO20090175L (no)	2009-03-11
US20120302600A1 (en)	2012-11-29
EP2035001B1 (en)	2011-11-09
EA200870599A1 (ru)	2009-06-30
DK2035001T3 (da)	2012-02-27
NZ573846A (en)	2012-01-12
MX2008015808A (es)	2009-02-17
KR20160013273A (ko)	2016-02-03
PL2035001T3 (pl)	2012-05-31
HK1121971A1 (en)	2009-05-08
KR20090017694A (ko)	2009-02-18
PT2035001E (pt)	2012-02-06
AU2007258366B2 (en)	2012-10-25
EP2035001A2 (en)	2009-03-18
CA2899472A1 (en)	2007-12-21
JP2009539984A (ja)	2009-11-19
US8383645B2 (en)	2013-02-26
JP5226678B2 (ja)	2013-07-03
BRPI0713694A2 (pt)	2012-10-30
ES2377149T3 (es)	2012-03-22
ZA200810790B (en)	2010-03-31
US20110251235A1 (en)	2011-10-13
CA2654982C (en)	2015-11-10

Publication	Publication Date	Title
UA96449C2 (en)	2011-11-10	Stable laquinimod preparations
CY1111470T1 (el)	2015-08-05	Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200833370A (en)	2008-08-16	Pharmaceutical composition containing low substituted hydroxypropylcellulose
TW200621737A (en)	2006-07-01	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ZA200807274B (en)	2009-11-25	Novel pyridine derivatives
MX2010006799A (es)	2010-10-05	Benzofuropirimidinonas como inhibidores de la proteina cinasa.
UA93709C2 (ru)	2011-03-10	12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MY154909A (en)	2015-08-28	Novel thiophene derivatives
TW200700406A (en)	2007-01-01	Novel thiophene derivatives
TW200716591A (en)	2007-05-01	Novel thiophene derivatives
TW200708511A (en)	2007-03-01	Novel thiophene derivatives
TW200716552A (en)	2007-05-01	Novel thiophene derivatives
MX2012007375A (es)	2012-07-30	3-ceto-n-propargil 1-aminoindano.
JO2973B1 (en)	2016-03-15	Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
TW200738670A (en)	2007-10-16	Novel thiophene derivatives
TW200508197A (en)	2005-03-01	Indolone-acetamide derivatives, processes for preparing them and their uses
WO2008003050A3 (en)	2009-05-28	Gallium nitrate formulations
TW200639156A (en)	2006-11-16	New compounds
WO2005117895A8 (en)	2006-05-18	Compositions comprising meloxicam
TW200626158A (en)	2006-08-01	Naphthaline derivatives
TW200509992A (en)	2005-03-16	Dosage form containing pantoprazole as active ingredient
TW200503785A (en)	2005-02-01	Dosage form containing (S)-pantoprazole as active ingredient
WO2006072070A3 (en)	2007-12-06	Pharmaceutical formulations of gallium salts
MXPA05007253A (es)	2005-12-14	Sales novedosas de derivados anticonvulsivantes.
TNSN08242A1 (en)	2009-10-30	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof